Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma symbols : Inzy save search
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 22:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
| Email alert
Add to watchlist
pharma nasdaq grants
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -2.46%
H: 2.45%
C: -2.81%
pharma conference
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 2.09%
H: 14.47%
C: 6.6%
inz-701 pharma report ongoing trials topline
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -0.7%
H: 1.75%
C: 0.35%
pharma business year financial results
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -1.23%
H: 8.51%
C: 8.33%
pharma ceo health care
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 13:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -1.23%
H: 8.51%
C: 8.33%
pharma conference health care
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2024
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 0.0%
H: 2.45%
C: 2.08%
pharma nasdaq grants
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 0.0%
H: 2.45%
C: 2.08%
pharma nasdaq grants
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-05 (Crawled : 13:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -0.76%
H: 2.54%
C: -1.03%
pharma nasdaq grants
Inozyme Pharma to Participate in Upcoming Investor Conferences - November 9, 2023
Published: 2023-11-09 (Crawled : 15:30) - biospace.com/
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: -7.3%
pharma
Inozyme Pharma to Participate in Upcoming Investor Conferences
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: -7.3%
pharma
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 0.67%
H: 8.14%
C: 6.31%
pharma business financial results
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-11-03 (Crawled : 20:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
| Email alert
Add to watchlist
pharma nasdaq grants
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 0.35%
H: 2.76%
C: -2.76%
pharma kidney presentation week
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
Published: 2023-10-10 (Crawled : 12:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -0.8%
H: 6.08%
C: 5.14%
rare pharma genomics study
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
Published: 2023-10-06 (Crawled : 12:30) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -0.53%
H: 4.03%
C: 3.76%
pharma research meeting bone
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -4.12%
H: 17.12%
C: 8.65%
inz-701 pharma positive ongoing trials
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Published: 2023-09-20 (Crawled : 13:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: 5.29%
H: 11.57%
C: 6.99%
pharma
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-09-06 (Crawled : 13:00) - globenewswire.com
INZY | $4.515 -1.42% 20K
|
Health Technology
|
| O: -0.83%
H: 2.3%
C: 1.46%
pharma nasdaq grants
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
ZCMD | $2.18 50.35% 24M
|
Commercial Services
RWOD | $12.0 50.06% 3.9M
|
n/a
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
MCB 4 | $38.545 16.45% 34K
|
Finance
BHAT | $1.06 11.58% 9.3K
|
Consumer Durables
Your saved searches
Save your searches and get alerts when important news are released.